Cancer News and Research

Latest Cancer News and Research

Light signaling pathways, circadian rhythms affect biological functions: Research

A new study of the genetic basis of circadian rhythms - the biological responses related to daily light exposure - has found that a few minutes of light exposure in a fungus directly affects a huge range of its biological functions, everything from reproduction to coloring and DNA repair.

27 Aug 2010

JVIR supplement to review thermal ablation usage in treating cancer

The unprecedented growth and promise of using thermal ablation to target and kill cancer is the subject of the Journal of Vascular and Interventional Radiology's August supplement, "Thermal Ablation 2010 At the Crossroads of Past Success, Current Goals and Future Technology."

27 Aug 2010

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.

27 Aug 2010

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Cascade Technologies, Inc. announced today that its wholly owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule.

27 Aug 2010

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

An experimental drug designed to treat cancers with a particular genetic fault has shown promising results in a small clinical trial.

27 Aug 2010

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

27 Aug 2010

Disulfiram drug effective in treating cocaine addiction: Research

Doctors have used the drug disulfiram to help patients stay sober for several decades. It interferes with the body's ability to metabolize alcohol, giving a fierce hangover to someone who consumes even a small amount of alcohol.More recently, disulfiram was shown to be effective in treating cocaine addiction as well, even though alcohol and cocaine affect the nervous system in different ways.

27 Aug 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

Spoonful of black rice bran contains more health promoting anthocyanin antioxidants than blueberries

Health conscious consumers who hesitate at the price of fresh blueberries and blackberries, fruits renowned for high levels of healthful antioxidants, now have an economical alternative, scientists reported here today at the 240th National Meeting of the American Chemical Society. It is black rice, one variety of which got the moniker "Forbidden Rice" in ancient China because nobles commandeered every grain for themselves and forbade the common people from eating it.

27 Aug 2010

V Foundation Wine Celebration raises fund for cancer research

The 12th Annual Wine Celebration benefitting The V Foundation took place August 6&7 in Napa Valley, raising $2.2 million for cancer research. The event, a signature fundraiser for sportscaster/coach Jim Valvano's eponymous foundation, has raised more than $35 million since 1998.

27 Aug 2010

SU2C, Virgin America enter partnership to raise awareness and funds for cancer research

Stand Up To Cancer (SU2C) and Virgin America, the California-based airline that is reinventing travel, today announce a unique partnership to raise awareness and funds for cancer research. As SU2C's Official Domestic Airline partner, Virgin America (with Virgin Unite) has pledged to support SU2C's mission through a multi-year in-kind travel partnership, Company fundraising and other joint efforts to drive awareness and funding for lifesaving cancer research.

27 Aug 2010

NICE suggests bortezomib, thalidomide for multiple myeloma patients

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance which recommends the drugs bortezomib and thalidomide as first-line therapies for some patients with multiple myeloma, a type of cancer that affects cells in the bone marrow.

27 Aug 2010

Veterans Affairs partners with NIH to grant award for substance abuse research in military personnel

The Department of Veterans Affairs is partnering with the National Institutes of Health (NIH) to award $6 million in grants for research examining the link between substance abuse and military deployments and combat-related trauma.

26 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Seven year Aspirin for cancer trial

A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.

26 Aug 2010

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Bio-Reference Laboratories, Inc. (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009.

26 Aug 2010

Preferred Imaging installs Naviscan Positron Emission Mammography scanner in new Plano facility

Preferred Imaging Centers has installed the Naviscan PEM scanner into its newest facility in Plano, TX, adding a dedicated breast imaging modality to its array of diagnostic tools. PEM (Positron Emission Mammography) scanners are high-resolution breast PET systems that show the location as well as the metabolic phase of a lesion. The metabolic view assists physicians in making the optimal patient care decision by providing an unprecedented ability to distinguish between benign and malignant lesions, what researchers term “specificity.”

26 Aug 2010

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

OXIS INTERNATIONAL, INC. is proud to announce that it has initiated active planning for the First World Congress on Ergothioneine, to be held in Los Angeles, California in July 2011 (the specific date will be announced at a later date).

26 Aug 2010

NeoPharm second-quarter net loss decreases to $0.8 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for various forms of cancer and other diseases, today announced its second quarter 2010 financial results.

26 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Light signaling pathways, circadian rhythms affect biological functions: Research

JVIR supplement to review thermal ablation usage in treating cancer

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Experimental drug PLX4032 holds promise against cancers with faulty BRAF gene

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Disulfiram drug effective in treating cocaine addiction: Research

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

Spoonful of black rice bran contains more health promoting anthocyanin antioxidants than blueberries

V Foundation Wine Celebration raises fund for cancer research

SU2C, Virgin America enter partnership to raise awareness and funds for cancer research

NICE suggests bortezomib, thalidomide for multiple myeloma patients

Veterans Affairs partners with NIH to grant award for substance abuse research in military personnel

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

Aethlon Medical receives approval for Chronic HCV Infection treatment

Seven year Aspirin for cancer trial

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Preferred Imaging installs Naviscan Positron Emission Mammography scanner in new Plano facility

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

NeoPharm second-quarter net loss decreases to $0.8 million

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in